Zacks Investment Research
24 Aug 2026, 14:40 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Bioventus (BVS) has achieved a year-to-date return of 93.3%, significantly outperforming its Medical sector average of 6.6%. — Strong price momentum and significant alpha generation relative to the sector usually attract further investor attention.
+0.40Amneal Pharmaceuticals (AMRX) holds a Zacks Rank #1 (Strong Buy) and has gained 42.1% year-to-date. — A top-tier analyst rating combined with strong YTD growth suggests a positive short-to-medium term outlook.
+0.30The Zacks Consensus Estimate for Bioventus' full-year earnings has increased by 1.3% over the past quarter. — Positive earnings estimate revisions are typically a lead indicator for stock price appreciation.
+0.20Continue reading
6 related stories
Search tags
The Medical sector currently ranks #6 out of 16 groups in the Zacks Sector Rank. — Moderate sector ranking indicates a neutral-to-positive environment for medical stocks but is not a primary catalyst.
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
